Nomura Holdings’s NovoCure NVCR Stock Holding History

Nomura Holdings’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-77,700	Closed	-$1M	–	2083
2025 Q3	$1M	Buy	77,700 +11,800	+18%	+$158K	﹤0.01%	1395
2025 Q2	$1.17M	Buy	+65,900	New	+$1.15M	﹤0.01%	962

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Nomura Holdings's NVCR Position: Q1 2022 in Review

Nomura Holdings sold out of NovoCure (NVCR) in Q1 2022, closing a stake of 5,137 shares — an estimated $386K sold.

Nomura Holdings first reported a position in NVCR in Q1 2020 and held it in 8 quarters. The position peaked at $10.3M in Q3 2020. 309 funds tracked by Wall St. Rank hold NVCR as of Q1 2022.

Nomura Holdings reported no remaining NovoCure position as of Q1 2022 after selling out during the quarter.
Nomura Holdings sold 5,137 NovoCure shares in Q1 2022, an estimated $386K.
Nomura Holdings first reported a position in NovoCure in Q1 2020 and held it in 8 quarters.
Nomura Holdings's NovoCure position peaked at $10.3M in Q3 2020.
309 funds tracked by Wall St. Rank held NovoCure as of Q1 2022.

Based on Nomura Holdings's 13F filing for Q1 2022, filed 18 May 2022.